Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

Toxicity of Aceporol 330 in Mice as Novel Solubilizer of Paclitaxel

  • Published : 2008.03.28
Download PDF
⟨ Previous Next ⟩

Abstract

The objective of this study was to investigate the single dose and 2-week repeated dose toxicity of Aceporol 330 in ICR mice following single intravenous administration and to compare its toxicity with a commercially available solubilizer of paclitaxel, Cremophor EL. In single dose toxicity test, $LD_{50}$ of Aceporol 330 in mice was estimated to be greater than maximum applicable dose, 4 ml/kg. However, $LD_{50}$ of Cremophor EL in male mice was determined to be 4 ml/kg. Maximum tolerated dose (MTD) of males and females in Aceporol 330-treated group and MTD of females in Cremophor EL-treated group were 3 ml/kg. MTD of males in Cremophor EL-treated group was less than 3 ml/kg. Characteristic toxic symptoms, and hematological and blood chemical changes were not observed after single dose and repeated dose of Aceporol 330 or Cremophor EL. No histopathological abnormalities were found in organs of all animal groups. Based on the linear pharmacokinetic property of paclitaxel and the higher $LD_{50}$ in mice, Aceporol 330 has a potential for use as a safer solubilizer for paclitaxel than Cremophor EL.

Keywords

References

  1. Cai S., Vijayan K., Cheng D., Lima E. M. and Discher D. E. (2007). Micelles of different morphologies--advantages of worm-like filomicelles of PEO-PCL in paclitaxel delivery. Pharm. Res. 24(11), 2099-109 https://doi.org/10.1007/s11095-007-9335-z
  2. Crown J. and O'Leary M. (2000). The taxanes: an update. Lancet. 355(9210), 1176-8 https://doi.org/10.1016/S0140-6736(00)02074-2
  3. Gelderblom H., Verweij J., Nooter K. and Sparreboom A. (2001). Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer. 37(13), 1590-8 https://doi.org/10.1016/S0959-8049(01)00171-X
  4. Kang B. K., Chon S. K., Kim S. H., Jeong S. Y., Kim M. S., Cho S. H., Lee H. B. and Khang G. (2004). Controlled release of paclitaxel from microemulsion containing PLGA and evaluation of anti-tumor activity in vitro and in vivo. Int. J. Pharm. 286(1-2), 147-56 https://doi.org/10.1016/j.ijpharm.2004.08.008
  5. Kim S. C., Kim D. W., Shim Y. H., Bang J. S., Oh H. S., Kim S. W., Seo M. H. (2001). In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J. Controlled Release. 72, 191-202 https://doi.org/10.1016/S0168-3659(01)00275-9
  6. Konno T., Watanabe J. and Ishihara K. J. (2003). Enhanced solubility of paclitaxel using water-soluble and biocompatible 2-methacryloyloxyethyl phosphorylcholine polymers. Biomed. Mater. Res. 65(2), 209-14
  7. Le Garrec D., Gori S., Luo L., Lessard D., Smith D. C., Yessine M. A., Ranger M. and Leroux J. C. (2004). Poly (N-vinylpyrrolidone)-block-poly(D,L-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation. J. Control Release. 99(1), 83-101 https://doi.org/10.1016/j.jconrel.2004.06.018
  8. Lee S. Y. (2002). Pharmacokinetics of the Paclitaxel of New Micelle Formulation. Ewha Womans University., Seoul, Korea
  9. Loos W. J., Szebeni J., ten Tije A. J., Verweij J., van Zomeren D. M., Chung K. N., Nooter K., Stoter G. and Sparreboom A. (2002). Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel. Anticancer Drugs. 13(7), 767-75 https://doi.org/10.1097/00001813-200208000-00012
  10. Mielke S., Sparreboom A. and Mross K. (2006). Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur. J. Cancer. 42(1), 24-30 https://doi.org/10.1016/j.ejca.2005.06.030
  11. Nuijen B., Bouma M., Schellens J. H. and Beijnen J. H. (2001). Progress in the development of alternative pharmaceutical formulations of taxanes. Invest. New Drugs. 19(2), 143-53 https://doi.org/10.1023/A:1010682916808
  12. Shimomura T., Fujiwara H., Ikawa S., Kigawa J. and Terakawa N. (1998). Effects of Taxol on blood cells. Lancet. 352(9127), 541-2
  13. Singla A. K., Garg A. and Aggarwal D. (2002). Paclitaxel and its formulations. Int. J. Pharm. 235(1-2), 179-92 https://doi.org/10.1016/S0378-5173(01)00986-3
  14. van Zuylen L., Verweij J., Sparreboom A. (2001a). Role of formulation vehicles in taxane pharmacology. Invest New Drugs. 19(2):125-41 https://doi.org/10.1023/A:1010618632738
  15. van Zuylen L., Karlsson M. O., Verweij J., Brouwer E., de Bruijn P., Nooter K., Stoter G. and Sparreboom A. (2001b). Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother. Pharmacol. 47(4), 309-18 https://doi.org/10.1007/s002800000215
  16. Weiss R. B., Donehower R. C., Wiernik P. H., Ohnuma T., Gralla R. J., Trump D. L., Baker J. R. Jr., Van Echo D. A., Von Hoff D. D. and Leyland-Jones B. (1990). Hypersensitivity reactions from taxol. J. Clin. Oncol. 8(7), 1263- 8

Cited by

  1. Intratumoral delivery of paclitaxel using a thermosensitive hydrogel in human tumor xenografts vol.36, pp.1, 2013, https://doi.org/10.1007/s12272-013-0013-x